{"task_id": "755ef9339d18d556", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 184/464)", "text": " intrathor\nacic involvement\n172\nHodgkin\u2019s Lymphoma\n\n--- Page 194 ---\nPROGNOSTIC ISSUES\nPROGNOSTIC FACTORS FOR EARLY STAGE DIS\nEASE\nage >50, bulky disease, ESR >50 mm/h without\nB symptoms or ESR >30 mm/h with B symptoms,\nanemia\nINTERNATIONAL PROGNOSTIC FACTOR PROJECT\nSCORE FOR ADVANCED HODGKIN\u2019S LYMPHOMA\n(HASENCLEVER SCORE)\n\u0002\nFACTORS\nage >45, male gender, Ann Arbor clin\nical stage IV, albumin <40 g/L [ <4 g/dL],\nhemoglobin <105\ng/L\n[ <10.5\ng/dL],\nWBC\n>15\u0003103/mL,\nlymphocyte\n<0.6\u0003103/mL,\nor\n<8% of total WBC count\n\u0002\nSCORING\n1 point per factor, with a score of 0 7\n\u0002\nUTILITY\nthe 5 year progression free survival was\n84, 77, 67, 60, 51, 42% for scores of 0, 1, 2, 3, 4, and\n5 7, respectively\nMANAGEMENT\nLIMITED STAGE (stage IA, IIA, and IB in some institu\ntions, 30%)\nABVD (doxorubicin, bleomycin, vinblas\ntine, dacarbazine) x2 cycles. PET scan afterward, if\ncomplete remission, 2 more cycles; otherwise, give\ninvolved field radiation. If stage IA low bulk high neck\n(above hyoid) or epitrochlear nodular lymphocyte\npredominant disease, involved field radiation only\nADVANCED STAGE (70%)\nABVD \u00036 cycles. Reas\nsess with CT and/or PET scan. If residual disease, con\nsider involved field irradiation. Alternative regimens\nMANAGEMENT (CONT\u2019D)\ninclude BEACOPP (bleomycin, etoposide, doxorubi\ncin, cyclophosphamide, vincristine, procarbazine, pre\ndnisone) combined with involved field radiotherapy\nor Stanford V regimen (doxorubicin, vinblastine,\nmechlorethamine, vincristine, bleomycin, etoposide,\nprednisone)\ncombined\nwith\ninvolved\nfield\nradiotherapy\nREFRACTORY OR RELAPSED DISEASE\nhigh dose\nchemotherapy with CBV (cyclophosphamide, BCNU,\netoposide) or BEAM (BCNU, etoposide, cytarabine,\nmelphalan) and irradiation plus autologous stem\ncell transplant. Overall, 40 50% of refractory disease\nand 60 70% of first relapse can be cured\nTREATMENT ISSUES\nINDICATIONS FOR AUTOLOGOUS STEM CELL\nTRANSPLANT\nprogression during first line che\nmotherapy, relapse <1 year after completion of che\nmotherapy, relapse with B symptoms or extranodal\nsites. Patients with relapse >1 year or only in pre\nviously unirradiated lymph nodes may or may not\nrequire transplant\nFOLLOW UP\nevery 3 months for the first 2 years,\nevery 6 months for the next 3 years, then annually.\nPay\nparticular\nattention\nto\nrelapse\n(10 30%),\nhypothyroidism (50%), dental caries, and second\nmalignancies (breast, lung, esophageal, stomach,\nthyroid, melanoma, cervical, AML)\nNon-Hodgkin\u2019s Lymphoma\nDIFFERENTIAL DIAGNOSIS OF LYMPHADENOPATHY\nINFECTIONS\n\u0002\nBACTERIAL\nlocal infections, brucellosis, leptospiro\nsis, lymphogranuloma venereum, typhoid fever\n\u0002\nATYPICAL\nTB, syphilis, Lyme disease\n\u0002\nVIRAL\nHIV, EBV, HSV, CMV, HBV, mumps,\nmeasles, rubella, dengue fever\n\u0002\nFUNGAL\nhistoplasmosis,\ncoccidioidomycosis,\ncryptococcosis\n\u0002\nPARASITIC\ntoxoplasmosis\nNEOPLASTIC\n\u0002\nLYMPHOMA\nHodgkin\u2019s, non Hodgkin\u2019s\n\u0002\nLEUKEMIA\n\u0002\nMETASTATIC CANCER\n\u0002\nLYMPHOPROLIFERATIVE\nCastleman\u2019s\ndisease,\nangioimmunoblastic lymphadenopathy, autoim\nmune lymphoproliferative disease\nINFLAMMATORY\nRA,\nSLE,\ndermatomyositis,\nStill\u2019s disease, Churg Strauss syndrome\nINFILTRATIVE\nsarcoidosis, amyloidosis, histiocy\ntosis, chronic granulomatous disease\nDIFFERENTIAL DIAGNOSIS OF LYMPHADENOPATHY\n(CONT\u2019D)\nOTHERS\nmedications (phenytoin), endocrine\n(hypothyroidism,\nAddison\u2019s\ndisease),\nserum\nsickness\nPATHOPHYSIOLOGY\nHISTOLOGIC TYPE (WHO CLASSIFICATION)\n\u0002\nINDOLENT B-CELL LYMPHOMAS\n\u0002\nFOLLICULAR LYMPHOMA (FL, 25%)\ngrade I (0 5\ncentroblasts/high power field), II (6 15 centro\nblasts/high power field), IIIA (>15 centroblasts/\nhigh power field, centrocytes present)\n\u0002\nMARGINAL ZONE LYMPHOMA (MZL, 5%)\nMALT,\nnodal, splenic\n\u0002\nMANTLE\nCELL\nLYMPHOMA (MCL, 7%)\nmantle\nzone, nodular, diffuse, blastoid variant\n\u0002\nSMALL LYMPHOCYTIC LYMPHOMA (SLL, 5 10%)\nidentical to chronic lymphocytic leukemia in\npathologic characteristics, but treated as low\ngrade B cell lymphoma\nNon-Hodgkin\u2019s Lymphoma\n173", "text_length": 3881, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 184/464)", "type": "chunk", "chunk_index": 183, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.498767", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.499500", "status": "complete", "chunks_added": 2}